Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer

References

• SchiffPBFantJHorowitzSBPromotion of microtubule assembly in vitro by taxolNature1979227665667423966
   PubMed Web of Science ®Google Scholar
• Ten TijeAJVerweijJLoosWJPharmacological effects of formulation vehicles: implications for cancer chemotherapyClin Pharmacokinet20034266568512844327
   PubMed Web of Science ®Google Scholar
• GelmonKThe taxoids: paclitaxel and docetaxelLancet1994344126712727967989
   PubMed Web of Science ®Google Scholar
• Boehnke MichaudLValeroVHortobagyiGNRisks and benefits of taxanes in breast and ovarian cancerDrug Safety20002340142811085347
   PubMed Web of Science ®Google Scholar
• WinerEPBerryDAWoolfSDugganDKornblithAHarrisLNFailure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia GroupB trial 9342J Clin Oncol2004222061206815169793
   PubMed Web of Science ®Google Scholar
• SparreboomAvan TellingenONooijenWJNonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor ELCancer Res199656211221158616858
   PubMed Web of Science ®Google Scholar
• van ZuylenLVerweijJSparreboomARole of formulation vehicles in taxane pharmacologyInvest New Drugs20011912514111392447
   PubMed Web of Science ®Google Scholar
• GelderblomHVerweijJNooterKCremophor EL: The drawbacks and advantages of vehicle selection for drug formulationEur J Cancer2001371590159811527683
   PubMed Web of Science ®Google Scholar
• JainRKBarriers to drug delivery in solid tumorsSci Am199427158658066425
   PubMed Web of Science ®Google Scholar
• KnemeyerIWientjesMGAuJLSCremophor reduces paclitaxel penetration into bladder wall during intravesical treatmentCancer Chemother Pharmacol19994424124810453726
   PubMed Web of Science ®Google Scholar
• KumarGNWalleUKBhallaKNBinding of Taxol to human plasma, albumin and alpha1-acid glycoproteinRes Commun Chem Pathol Pharmacol1993803373448102493
   PubMedGoogle Scholar
• SparreboomAVerweijJvan der BurgMELoosWJBrouwerEViganòLDisposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivoClin Cancer Res19984193719429717822
   PubMed Web of Science ®Google Scholar
• PostmaTJVermorkenJBLieftingAJMPaclitaxel-induced neuropathyAnn Oncol199564894947669713
   PubMed Web of Science ®Google Scholar
• OnettoNCanettaRWinogradBOverview of taxol safetyJ Natl Cancer Inst199315131139
   Google Scholar
• de GroenPCAksamitAJRakelaJCentral nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterolN Engl J Med19873178618663306386
   PubMed Web of Science ®Google Scholar
• WindebankAJBlexrudMDde GroenPCPotential neurotoxicity of the solvent vehicle for cyclosporineJ Pharmacol Exp Ther1994268105110568113961
   PubMed Web of Science ®Google Scholar
• Aventis Pharmaceuticals IncTaxotere (docetaxel): prescribing informationBridgewater, NJAventis Pharmaceuticals2002
   Google Scholar
• BoerHMMoorer-van DelftCMMullerLJUltrastructural neuropathologic effects of Taxol on neurons of the fresh-water snail Lymnaea stagnalisJ Neurooncol19952549578523089
   PubMed Web of Science ®Google Scholar
• BratDJWindebankAJBrimijoinSEmulsifier for intravenous cyclosporine inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastomaJ Pharmacol Exp Ther19922618038101578386
   PubMed Web of Science ®Google Scholar
• CrownJO’LearyMThe taxanes: an updateLancet200035592101176117810791395
   PubMed Web of Science ®Google Scholar
• NewPZJacksonCERinaldiDPeripheral neuropathy secondary to docetaxel (Taxotere)Neurology1996461081118559355
   PubMed Web of Science ®Google Scholar
• PronkLCHikensPHvan den BentMJCorticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxelAnticancer Drugs199897597649840720
   PubMed Web of Science ®Google Scholar
• VerweijJClavelMChevalierBPaclitaxel (Taxol) and docetaxel (Taxotere): not simply two of kindAnn Oncol199454955057918121
   PubMed Web of Science ®Google Scholar
• FreilichRJBalmacedaCSeidmanADMotor neuropathy due to docetaxel and paclitaxelNeurology1996471151188710063
   PubMed Web of Science ®Google Scholar
• IbrahimNKDesaiNLeghaSSoon-ShiongPTheriaultRLRiveraEPhase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxelClin Cancer Res200281038104412006516
   PubMed Web of Science ®Google Scholar
• SparreboomAvan ZuylenLBrouwerELoosWJde BruijnPGelderblomHCremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implicationsCancer Res19995971454145710197613
   PubMed Web of Science ®Google Scholar
• SchnitzerJEOhPAntibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endotheliumAm J Physiol19922636 Pt 2H1872H18791481911
   PubMedGoogle Scholar
• BourasTLisantiMPPestelliRGCaveolin-1 in breast cancerCancer Biol Ther200431093194115539932
   PubMed Web of Science ®Google Scholar
• YangGTruongLDTimmeTLElevated expression of caveolin is associated with prostate and breast cancerClin Cancer Res199848187318809717814
   PubMed Web of Science ®Google Scholar
• RoyVLaplantBRGrossGGfor the North Central Cancer Treatment GroupPhase II trial of weekly nab (nanoparticle albuminbound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (NO531)Ann Oncol20092044945319087987
   PubMed Web of Science ®Google Scholar
• WatkinsGDouglas-JonesABryceRIncreased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomesProstaglandins Leukot Essent Fatty Acids200572426727215763438
   PubMed Web of Science ®Google Scholar
• PartonRGSimonsKThe multiple faces of caveolaeNat Rev Mol Cell Biol20078318519417318224
   PubMed Web of Science ®Google Scholar
• PelkmansLPuntenerDHeleniusALocal actin polymerization ad dynamin recruitment in SV40 induced internalization of caveolaeScience2002296556753553911964480
   PubMed Web of Science ®Google Scholar
• DesaiNPTrieuVHwangLYWuRSoon-ShiongPGradisharWJImproved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus plysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC statusAnticancer Drugs200819989990918766004
   PubMed Web of Science ®Google Scholar
• GreenMRManikhasGMOrlovSAfanasyevBMakhsonAMBharPAbraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-lung cancerAnn Oncol20061781263126816740598
   PubMed Web of Science ®Google Scholar
• DesaiNTrieuVYaoZIncreased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxelClin Cancer Res20061241317132416489089
   PubMed Web of Science ®Google Scholar
• FerraraNVEGF as a therapeutic target in cancerOncology200569Suppl 3111616301831
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJNovotnyWBevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochem Biophys Res Commun200533332833515961063
   PubMed Web of Science ®Google Scholar
• McDaidHMLopez-BarconsLGrossmanALiaMKellerSPérez-SolerREnhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplantsCancer Res2005652854286015805287
   PubMed Web of Science ®Google Scholar
• MiyaharaYYoshidaSMotoyamaSTateiwaYHamanaSMaruoTEffect of cis-diammine dichloroplatinum on vascular endothelial growth factor expression in uterine cervical carcinomaEur J Gynaecol Oncol200425333915053059
   PubMed Web of Science ®Google Scholar
• WildRDingsRPSubramanianICarboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VEGFInt J Cancer200411034335115095298
   PubMed Web of Science ®Google Scholar
• MillsPJParkerBJonesVAdlerKAPerezCJJohnsonSThe effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancerClin Cancer Res2004104998500315297400
   PubMed Web of Science ®Google Scholar
• RiedelFGotteKGoesslerUSadickHTargeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell linesAnticancer Res2004242179218315330158
   PubMed Web of Science ®Google Scholar
• SweeneyCJMillerKDSissonsSENozakiSHeilmanDKShenJThe antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factorsCancer Res2001613369337211309294
   PubMed Web of Science ®Google Scholar
• VolkLDFlisterMJBivensCMStutzmanADesaiNTrieuVHuman breast cancer is significantly enhanced by concurrent anti–vascular endothelial growth factor A therapyNeoplasia20081061362318516298
   PubMed Web of Science ®Google Scholar
• NymanDWCampbellKJHershEPhase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignanciesJ Clin Oncol2005237785779316258082
   PubMed Web of Science ®Google Scholar
• DamascelliBCantuGMattavelliFIntraarterial chemotherapy with polyoxyethilated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007)Cancer2001922592260211745194
   PubMed Web of Science ®Google Scholar
• DamascelliBPatelliGLanocitaRA novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue:preliminary findingsAm J Roentgenol200318125326012818869
   PubMed Web of Science ®Google Scholar
• GardnerERDahutWLScriptureCDJonesJAragon-ChingJBDesaiNRandomized crossover pharmacokinetic study of solvent-based paclitaxel and nab paclitaxelClin Cancer Res200814134200420518594000
   PubMed Web of Science ®Google Scholar
• IbrahimNKSamuelsBPageRDovalDPatelKMRaoSCMulticenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancerJ Clin Oncol200523256019602616135470
   PubMed Web of Science ®Google Scholar
• BlumJLSavinMAEdelmanGPippenJERobertNSandbachJLong term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel [abstract]J Clin Oncol20042214 SupplAbstract 543
   Google Scholar
• LinkJSWaismanJRNguyenBBevacizumab and albumine-bound paclitaxel treatment in metastatic breast cancerClin Breast Cancer20071077978318021479
   PubMed Web of Science ®Google Scholar
• GradisharWCortesJClinical efficacy and emerging therapeutic utilization of novel taxanesEJC Supplements20081061221
   Google Scholar
• ConlinAKSeidmanADMoynahanRandomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2 negative metastatic breast cancer: An initial interim safety report [abstract]J Clin Oncol20072518S part I1104
   Google Scholar
• BlumJLSavinMAEdelmanGPippenJERobertNJGeisterBVPhase II study of weekly albumin – bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanesClin Breast Cancer200711580586
   Web of Science ®Google Scholar
• SchwartzbergLSArenaFMintzerDPhase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC):interim results [abstract]Breast Cancer Res Treat2006100Suppl 11096
   Google Scholar
• GradisharWJTjulandinSDavidsonNShawHDesaiNBharPPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol200523317768777116204007
   PubMed Web of Science ®Google Scholar
• GradisharWKrasnojonDCheporovSManikhasGClawsonAHawkinsMJRandomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)J Clin Oncol200725Suppl18S
   Google Scholar
• DranitsarisGCottrelWSpirovskiBEconomic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancerJ Oncol Pharm Pract20081126(Epub ahead of print)
   Google Scholar
• RobidouxABuyseMBuzdarANeoadjuvant chemotherapy with sequential weekly nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane) followed by 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in locally advanced breast cancer (LABC): a phase II trial of the NSABP Foundation research programs (FRP) [abstract]Breast Cancer Res Treat2006100Suppl 13068(abstract)
   Google Scholar
• SomloGPazBShenJA randomized phase II neoadjuvant trial in patients with stage II–III and inflammatory breast cancerBreast Cancer Res Treat20071065073
   Web of Science ®Google Scholar
• DanielBRDossHGianVBiweekly neoadjuvant gemcitabine, epirubicin, and nano-particle albumin bound (nab) paclitaxel (GEA) with tumor SPARC analysis correlated with pathological responses: Results of a multicenter phase II trialJ Clin Oncol20072518S part I11060
   Google Scholar